About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 419402, 10 pages
http://dx.doi.org/10.1155/2012/419402
Review Article

Molecular Imaging in Therapeutic Efficacy Assessment of Targeted Therapy for Nonsmall Cell Lung Cancer

Yanni Hu,1,2,3,4 Mei Tian,1,2,3,4 and Hong Zhang1,2,3,4

1Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China
2Medical PET Center, Zhejiang University, Hangzhou 310009, China
3Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou 310009, China
4Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou 310009, China

Received 28 December 2011; Accepted 30 January 2012

Academic Editor: Yasuhisa Fujibayashi

Copyright © 2012 Yanni Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar
  2. S. H. Landis, T. Murray, S. Bolden, and P. A. Wingo, “Cancer Statistics, 1999,” Ca-A Cancer Journal for Clinicians, vol. 49, no. 1, pp. 8–31, 1999. View at Scopus
  3. National Cancer Institute, Surveillance, Epidemiology and End Results, http://seer.cancer.gov/.
  4. E. E. Vokes, J. D. Bitran, and N. J. Vogelzang, “Chemotherapy for non-small cell lung cancer; The continuing challenge,” Chest, vol. 99, no. 6, pp. 1326–1328, 1991. View at Scopus
  5. C. M. Haskell, “Chemotherapy and survival of patients with non-small cell lung cancer; A contrary view,” Chest, vol. 99, no. 6, pp. 1325–1326, 1991. View at Scopus
  6. G. Buccheri, “Chemotherapy and survival in non-small cell lung cancer; The old vexata questio,” Chest, vol. 99, no. 6, pp. 1328–1329, 1991. View at Scopus
  7. S. Burdett, S. Burdett, R. Stephens et al., “Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4617–4625, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Grossi, M. Aita, C. Defferrari et al., “Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach,” Oncologist, vol. 14, no. 5, pp. 497–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. H. Schiller, D. Harrington, C. P. Belani et al., “Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer,” New England Journal of Medicine, vol. 346, no. 2, pp. 92–98, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. F. A. Shepherd, “Chemotherapy for non-small cell lung cancer: have we reached a new plateau?” Seminars in Oncology, vol. 26, supplement 4, pp. 3–11, 1999.
  11. A. Martoni, A. Marino, F. Sperandi et al., “Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer,” European Journal of Cancer, vol. 41, no. 1, pp. 81–92, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. J. Duffy, “Predictive markers in breast and other cancers: a review,” Clinical Chemistry, vol. 51, no. 3, pp. 494–503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. J. Duffy and J. Crown, “A personalized approach to cancer treatment: how biomarkers can help,” Clinical Chemistry, vol. 54, no. 11, pp. 1770–1779, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Francis and B. Solomon, “The current status of targeted therapy for non-small cell lung cancer,” Internal Medicine Journal, vol. 40, no. 9, pp. 611–618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. T. S. Mok, Y. L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. D. H. Johnson, L. Fehrenbacher, W. F. Novotny et al., “Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2184–2191, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Sandler, R. Gray, M. C. Perry et al., “Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer,” New England Journal of Medicine, vol. 355, no. 24, pp. 2542–2550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Gridelli, C. Butts, F. Ciardiello, R. Feld, C. Gallo, and F. Perrone, “An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial,” Clinical Lung Cancer, vol. 9, no. 4, pp. 235–238, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Maemondo, A. Inoue, K. Kobayashi et al., “Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR,” New England Journal of Medicine, vol. 362, no. 25, pp. 2380–2388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Govindan, “Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 5, supplement 6, no. 12, p. S433, 2010.
  21. F. Janku, I. Garrido-Laguna, L. B. Petruzelka, D. J. Stewart, and R. Kurzrock, “Novel therapeutic targets in non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 6, no. 9, pp. 1601–1612, 2011. View at Publisher · View at Google Scholar
  22. J. E. Larsen, T. Cascone, D. E. Gerber, J. V. Heymach, and J. D. Minna, “Targeted therapies for lung cancer: clinical experience and novel agents,” Cancer Journal, vol. 17, no. 6, pp. 512–527, 2011. View at Publisher · View at Google Scholar
  23. A. Chang, “Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC,” Lung Cancer, vol. 71, no. 1, pp. 3–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Inoue, T. Suzuki, T. Fukuhara et al., “Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations,” Journal of Clinical Oncology, vol. 24, no. 21, pp. 3340–3346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Yamazaki, I. Kinoshita, N. Sukoh et al., “A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations,” British Journal of Cancer, vol. 95, no. 8, pp. 998–1004, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. D. M. Jackman, B. Y. Yeap, N. I. Lindeman et al., “Phase II clinical trial of chemotherapy-naïve patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 25, no. 7, pp. 760–766, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Sunaga, Y. Tomizawa, N. Yanagitani et al., “Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy,” Lung Cancer, vol. 56, no. 3, pp. 383–389, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. L. V. Sequist, D. W. Bell, T. J. Lynch, and D. A. Haber, “Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 25, no. 5, pp. 587–595, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. P. M. Fidias, S. R. Dakhil, A. P. Lyss et al., “Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 27, no. 4, pp. 591–598, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. T. E. Stinchcombe and M. A. Socinski, “Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy,” Journal of Thoracic Oncology, vol. 4, no. 2, pp. 243–250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. G. V. Scagliotti, P. Parikh, J. Von Pawel et al., “Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3543–3551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. O. P. Joon, S. W. Kim, S. A. Jin et al., “Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5233–5239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Vergote, G. J. S. Rustin, E. A. Eisenhauer et al., “Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer],” Journal of the National Cancer Institute, vol. 92, no. 18, pp. 1534–1535, 2000. View at Scopus
  34. World Health Organization, WHO Handbook for Reporting Results of Cancer Treatment, World Health Organization, Geneva, Switzerland, 1979.
  35. Food and Drug Administration, Reinventing the Regulation of Cancer Drugs: Accelerating Approval and Expanding Access, National Performance Review, Washington, DC, USA, 1996.
  36. A. B. Sandler, J. Nemunaitis, C. Denham et al., “Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 122–130, 2000. View at Scopus
  37. C. Sederholm, G. Hillerdal, K. Lamberg et al., “Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish lung cancer study group,” Journal of Clinical Oncology, vol. 23, no. 33, pp. 8380–8388, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. C. M. R. Lima, N. A. Rizvi, C. Zhang et al., “Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC,” Annals of Oncology, vol. 15, no. 3, pp. 410–418, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Grossi, F. de Marinis, V. Gebbia et al., “A randomized phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 2, pp. 369–375, 2012. View at Publisher · View at Google Scholar
  40. K. R. Birchard, J. K. Hoang, J. E. Herndon Jr, and E. F. Patz Jr, “Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival,” Cancer, vol. 115, no. 3, pp. 581–586, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Buyse and P. Piedbois, “On the relationship between response to treatment and survival time,” Statistics in Medicine, vol. 15, no. 24, pp. 2797–2812, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Buyse, P. Thirion, R. W. Carlson, T. Burzykowski, G. Molenberghs, and P. Piedbois, “Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis,” The Lancet, vol. 356, no. 9227, pp. 373–378, 2000. View at Scopus
  43. Administration FaD, Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, Services UDoHaH, Washington, DC, USA, 2005.
  44. M. Buyse, T. Burzykowski, K. Carroll et al., “Progression-free survival is a surrogate for survival in advanced colorectal cancer,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5218–5224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. P. N. Lara Jr, M. W. Redman, K. Kelly et al., “Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest oncology group randomized trials,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 463–467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. Q. Shi and D. J. Sargent, “Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials,” International Journal of Clinical Oncology, vol. 14, no. 2, pp. 102–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Choi, “Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model,” Current Oncology Reports, vol. 7, no. 4, pp. 307–311, 2005. View at Scopus
  48. J. C. Yang, L. Haworth, R. M. Sherry et al., “A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,” New England Journal of Medicine, vol. 349, no. 5, pp. 427–434, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Fukuoka, S. Yano, G. Giaccone et al., “Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 21, no. 12, pp. 2237–2246, 2003. View at Publisher · View at Google Scholar
  50. M. G. Kris, R. B. Natale, R. S. Herbst et al., “Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial,” Journal of the American Medical Association, vol. 290, no. 16, pp. 2149–2158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Perez-Soler, “Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer,” Clinical Lung Cancer, vol. 6, no. 1, pp. S20–S23, 2004. View at Scopus
  52. J. Wang, N. Wu, M. D. Cham, and Y. Song, “Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy,” American Journal of Roentgenology, vol. 193, no. 4, pp. 1090–1096, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. J. S. W. Lind, M. R. Meijerink, A. M. C. Dingemans et al., “Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?” European Radiology, vol. 20, no. 12, pp. 2890–2898, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Choi, C. Charnsangavej, S. C. Faria et al., “Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1753–1759, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. A. D. Smith, S. N. Shah, B. I. Rini, M. L. Lieber, and E. M. Remer, “Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy,” American Journal of Roentgenology, vol. 194, no. 6, pp. 1470–1478, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. P. S. Tofts, G. Brix, D. L. Buckley et al., “Estimating kinetic parameters from dynamic contrast-enhanced T1- weighted MRI of a diffusable tracer: standardized quantities and symbols,” Journal of Magnetic Resonance Imaging, vol. 10, no. 3, pp. 223–232, 1999. View at Publisher · View at Google Scholar · View at Scopus
  57. I. Lee and K. Shogen, “Mechanisms of enhanced tumoricidal efficacy of multiple small dosages of ranpirnase, the novel cytotoxic ribonuclease, on lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 62, no. 2, pp. 337–346, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. A. M. Dingemans, A. J. de Langen, V. van den Boogaart, et al., “First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging,” Annals of Oncology, vol. 22, no. 3, pp. 559–566, 2011.
  59. P. F. Daly and J. S. Cohen, “Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review,” Cancer Research, vol. 49, no. 4, pp. 770–779, 1989. View at Scopus
  60. H. Hanaoka, Y. Yoshioka, I. Ito, K. Niitu, and N. Yasuda, “In vitro characterization of lung cancers by the use of 1H nuclear magnetic resonance spectroscopy of tissue extracts and discriminant factor analysis,” Magnetic Resonance in Medicine, vol. 29, no. 4, pp. 436–440, 1993. View at Scopus
  61. W. A. Weber, V. Petersen, B. Schmidt et al., “Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2651–2657, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Mileshkin, R. J. Hicks, B. G.M. Hughes et al., “Changes in F18-fluorodeoxyglucose and F18-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib,” Clinical Cancer Research, vol. 17, no. 10, pp. 3304–3315, 2011. View at Publisher · View at Google Scholar
  63. A. Achmad, H. Hanaoka, H. Yoshioka et al., “Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using (64) Cu-labeled cetuximab positron emission tomography,” Cancer Science, vol. 103, no. 3, pp. 600–605, 2012. View at Publisher · View at Google Scholar
  64. C. Wu, Z. Tang, W. Fan et al., “In vivo Positron Emission Tomography (PET) imaging of Mesenchymal - Epithelial Transition (MET) receptor,” Journal of Medicinal Chemistry, vol. 53, no. 1, pp. 139–146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Young, R. Baum, U. Cremerius et al., “Measurement of clinical and subclinical tumour response using [F18]- fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations,” European Journal of Cancer, vol. 35, no. 13, pp. 1773–1782, 1999. View at Publisher · View at Google Scholar
  66. L. K. Shankar, J. M. Hoffman, S. Bacharach et al., “Consensus recommendations for the use of F18-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials,” Journal of Nuclear Medicine, vol. 47, no. 6, pp. 1059–1066, 2006. View at Scopus
  67. D. S. Binns, A. Pirzkall, W. Yu et al., “Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer,” European Journal of Nuclear Medicine and Molecular Imaging, pp. 1–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Kahraman, M. Scheffler, T. Zander et al., “Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using F18-FDG and 3'-deoxy-3'- F18-fluorothymidine PET,” Journal of Nuclear Medicine, vol. 52, no. 12, pp. 1871–1877, 2011. View at Publisher · View at Google Scholar
  69. L. F. de Geus-Oei, H. F. M. Van Der Heijden, E. P. Visser et al., “Chemotherapy response evaluation with F18-FDG PET in patients with non-small cell lung cancer,” Journal of Nuclear Medicine, vol. 48, no. 10, pp. 1592–1598, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend, “Time course of early response to chemotherapy in non-small cell lung cancer patients with F18-FDG PET/CT,” Journal of Nuclear Medicine, vol. 48, no. 5, pp. 744–751, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Decoster, D. Schallier, H. Everaert et al., “Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (F18DG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC),” Lung Cancer, vol. 62, no. 1, pp. 55–61, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Imamura, K. Azuma, S. Kurata et al., “Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy,” Lung Cancer, vol. 71, no. 1, pp. 49–54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. A. D. van den Abbeele and R. D. Badawi, “Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs),” European Journal of Cancer, vol. 38, pp. S60–65, 2002. View at Scopus
  74. G. Antoch, J. Kanja, S. Bauer et al., “Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors,” Journal of Nuclear Medicine, vol. 45, no. 3, pp. 357–365, 2004. View at Scopus
  75. S. Stroobants, J. Goeminne, M. Seegers et al., “F18DG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®),” European Journal of Cancer, vol. 39, no. 14, pp. 2012–2020, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Prenen, C. Deroose, P. Vermaelen et al., “Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography,” Anticancer Research, vol. 26, no. 2, pp. 1247–1252, 2006. View at Scopus
  77. H. Su, C. Bodenstein, R. A. Dumont et al., “Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors,” Clinical Cancer Research, vol. 12, no. 19, pp. 5659–5667, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Assadian, A. Aliaga, R. F. Del Maestro, A. C. Evans, and B. J. Bedell, “FDG-PET imaging for the evaluation of antiglioma agents in a rat model,” Neuro-Oncology, vol. 10, no. 3, pp. 292–299, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. D. S. Dorow, C. Cullinane, N. Conus et al., “Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 4, pp. 441–452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. O. Schillaci, “Single-Photon Emission Computed Tomography/Computed Tomography in Lung Cancer and Malignant Lymphoma,” Seminars in Nuclear Medicine, vol. 36, no. 4, pp. 275–285, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. D. Piwnica-Worms, M. L. Chiu, M. Budding, J. F. Kronauge, R. A. Kramer, and J. M. Croop, “Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex,” Cancer Research, vol. 53, no. 5, pp. 977–984, 1993. View at Scopus
  82. H. K. Mohan and K. A. Miles, “Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis,” Journal of Nuclear Medicine, vol. 50, no. 3, pp. 376–381, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Talapatra and C. B. Thompson, “Growth factor signaling in cell survival: implications for cancer treatment,” Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 3, pp. 873–878, 2001. View at Scopus
  84. J. R. Woodburn, “The epidermal growth factor receptor and its inhibition in cancer therapy,” Pharmacology and Therapeutics, vol. 82, no. 2-3, pp. 241–250, 1999. View at Publisher · View at Google Scholar · View at Scopus
  85. V. Rusch, J. Baselga, C. Cordon-Cardo et al., “Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung,” Cancer Research, vol. 53, no. 10, pp. 2379–2385, 1993. View at Scopus
  86. F. R. Hirsch, M. Varella-Garcia, P. A. Bunn et al., “Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis,” Journal of Clinical Oncology, vol. 21, no. 20, pp. 3798–3807, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Wells, “EGF receptor,” International Journal of Biochemistry and Cell Biology, vol. 31, no. 6, pp. 637–643, 1999.
  88. D. Busse, R. S. Doughty, T. T. Ramsey et al., “Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity,” Journal of Biological Chemistry, vol. 275, no. 10, pp. 6987–6995, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. A. M. Petit, J. Rak, M. C. Hung et al., “Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors,” American Journal of Pathology, vol. 151, no. 6, pp. 1523–1530, 1997. View at Scopus
  90. N. Sunaga, N. Oriuchi, K. Kaira et al., “Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer,” Lung Cancer, vol. 59, no. 2, pp. 203–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. G. J. Riely, M. G. Kris, B. Zhao et al., “Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus,” Clinical Cancer Research, vol. 13, no. 17, pp. 5150–5155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. R. T. Ullrich, T. Zander, B. Neumaier et al., “Early detection of Erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F18]-fluoro-L-thymidine ([F18]FLT) positron emission tomography (PET),” PLoS ONE, vol. 3, no. 12, Article ID e3908, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. T. Zander, M. Scheffler, L. Nogova, et al., “Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography,” Journal of Clinical Oncology, vol. 29, no. 13, pp. 1701–1708, 2011.
  94. R. Pirker, J. R. Pereira, A. Szczesna et al., “Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial,” The Lancet, vol. 373, no. 9674, pp. 1525–1531, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. F. D. Fabio, C. Pinto, F. L. Rojas Llimpe et al., “The predictive value of F18-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab,” Gastric Cancer, vol. 10, no. 4, pp. 221–227, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Takeuchi, S. Zhao, Y. Kuge et al., “F18-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts,” Oncology Reports, vol. 26, no. 3, pp. 725–730, 2011. View at Publisher · View at Google Scholar
  97. E. Cabebe and H. Wakelee, “Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors,” Current Treatment Options in Oncology, vol. 8, no. 1, pp. 15–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. N. Ferrara, “The role of vascular endothelial growth factor in pathological angiogenesis,” Breast Cancer Research and Treatment, vol. 36, no. 2, pp. 127–137, 1995. View at Publisher · View at Google Scholar · View at Scopus
  99. N. Weidner, J. P. Semple, W. R. Welch, and J. Folkman, “Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma,” New England Journal of Medicine, vol. 324, no. 1, pp. 1–8, 1991. View at Scopus
  100. I. M. E. Desar, C. M. L. van Herpen, H. W. M. van Laarhoven, J. O. Barentsz, W. J. G. Oyen, and W. T. A. van der Graaf, “Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy,” Cancer Treatment Reviews, vol. 35, no. 4, pp. 309–321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Sandler, R. Gray, M. C. Perry et al., “Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer,” New England Journal of Medicine, vol. 355, no. 24, pp. 2542–2550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. M. A. Pysz, S. S. Gambhir, and J. K. Willmann, “Molecular imaging: current status and emerging strategies,” Clinical Radiology, vol. 65, no. 7, pp. 500–516, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. D. A. Mankoff, “A definition of molecular imaging,” Journal of Nuclear Medicine, vol. 48, no. 6, pp. 18N–21N, 2007.